Price · as of 2024-12-31
$3.95
Market cap 389.18M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $820.83 | +20,680.51% |
| Intrinsic Value(DCF) | $27.34 | +592.15% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $0.00 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $37.08 | |||
| 2014 | $2.84 | $0.02 | |||
| 2015 | $24.89 | $130.04 | $2,790.90 | $5.13 | $0.00 |
| 2016 | $22.90 | $425.60 | $21.18 | $0.00 | $24.43 |
| 2017 | $34.07 | $34.67 | $4.50 | $0.00 | $86.02 |
| 2018 | $18.04 | $33.72 | $6.80 | $0.39 | $75.50 |
| 2019 | $14.64 | $26.82 | $3.99 | $0.00 | $0.00 |
| 2020 | $19.95 | $49.87 | $374.36 | $0.00 | $0.00 |
| 2021 | $4.40 | $21.13 | $2.41 | $0.00 | $78.23 |
| 2022 | $1.99 | $23.57 | $0.16 | $0.00 | $63.07 |
| 2023 | $2.59 | $34.15 | $0.00 | $0.00 | $148.36 |
| 2024 | $1.25 | $820.83 | $0.75 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cellectis S.A.'s (CLLS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $820.83
- Current price
- $3.95
- AI upside
- +20,680.51%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$27.34
+592.15% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CLLS | Cellectis S.A. | $3.95 | 389.18M | +20,681% | +592% | — | — | -3.10 | 0.87 | 2.74 | 5.83 | — | 0.87 | 77.88% | -143.48% | -88.57% | -34.02% | 165.71% | -10.22% | 0.70 | -7.99 | 1.73 | 1.70 | 5.47 | -7684.00% | 539748.00% | -17562.00% | 17.18% | 0.13 | -54.33% | 0.00% | 0.00% | 0.12% | 0.93 | -2.83 | -1.33 | -0.96 |
| ACIU | AC Immune S.A. | $2.93 | 294.76M | +1,817% | -50% | — | — | -3.77 | 1.71 | 7.03 | -0.66 | — | 3.10 | -129.12% | -191.80% | -186.44% | -37.31% | -787.64% | -24.61% | 0.05 | -393.82 | 1.71 | 1.65 | 0.63 | -2031.00% | 8451.00% | -20663.00% | 34.00% | 0.65 | 981.44% | 0.00% | 0.00% | 0.00% | -0.61 | 0.49 | 1.17 | -1.52 |
| ALDX | Aldeyra Therapeutics, Inc… | $5.46 | 328.49M | — | — | — | — | 0.00 | 0.00 | — | 1.55 | — | 0.00 | 0.00% | — | — | -152.98% | 0.00% | -93.94% | 0.35 | -18.51 | 2.58 | 2.52 | 1.55 | -4043.00% | — | 7717335287.00% | -9879606.86% | -1.20 | 649.97% | 0.00% | 0.00% | 16150447.97% | 1545737.39 | 1.63 | — | -8.67 |
| AMRN | Amarin Corporation plc | $13.80 | 285.42M | +2,553% | -43% | -73% | +374% | -2.65 | 0.45 | 0.95 | 0.93 | -7.95 | 0.46 | 35.60% | -40.15% | -35.95% | -15.83% | -41.74% | -10.83% | 0.02 | -13113.86 | 3.31 | 2.31 | 1.53 | 3333.00% | -2551.00% | -55089.00% | -14.25% | -0.17 | -14.11% | 0.00% | 0.00% | 0.00% | 0.75 | 2.21 | -0.30 | -2.13 |
| ANRO | Alto Neuroscience, Inc. | $19.69 | 611.7M | — | — | — | — | -1.42 | 0.58 | — | 0.93 | -1.67 | 0.58 | 0.00% | — | — | -153.99% | 95.25% | -46.51% | 0.11 | 49.90 | 16.92 | 16.81 | 2.20 | 8519.00% | — | 4594.00% | -56.68% | -4.74 | 68.72% | 0.00% | 0.00% | 90.14% | 0.93 | 1.29 | — | 0.72 |
| DBVT | DBV Technologies S.A. | $20.99 | 502.12M | -17% | — | — | — | -0.71 | 2.93 | — | -0.50 | -1.28 | 2.94 | 0.00% | — | — | -135.96% | -2872.45% | -91.63% | 0.28 | — | 1.43 | 1.38 | 0.22 | 5526.00% | -10000.00% | 3297.00% | -132.98% | -3.36 | -2637.08% | 0.00% | 0.00% | 0.06% | -0.46 | -0.52 | — | -10.66 |
| DRTS | Alpha Tau Medical Ltd. | $7.76 | 661.65M | — | — | — | — | -6.09 | 3.09 | — | -4.83 | -85.26 | 3.09 | 0.00% | — | — | -43.16% | -228.37% | -32.80% | 0.20 | -104.77 | 7.40 | 6.91 | 0.04 | 714.00% | — | -960.00% | -11.39% | -2.28 | -139.53% | 0.00% | 0.00% | 0.93% | -4.06 | -6.64 | — | 1.93 |
| KRRO | Korro Bio, Inc. | $12.13 | 114.23M | — | -2% | — | — | -2.38 | 1.24 | 87.71 | -1.33 | — | 1.24 | 100.00% | -4047.12% | -3680.36% | -50.61% | -158.39% | -37.32% | 0.28 | — | 8.79 | 8.54 | 0.12 | -8235.00% | — | 380.00% | -39.15% | -4.02 | -134.38% | 0.00% | 0.00% | 0.00% | -1.28 | -1.51 | 51.90 | -0.55 |
| LRMR | Larimar Therapeutics, Inc… | $5.31 | 454.48M | — | — | — | — | -2.30 | 1.08 | — | -0.08 | -4.03 | 1.08 | 0.00% | — | — | -63.58% | 3005.12% | -54.43% | 0.03 | — | 8.02 | 7.58 | 0.31 | 5714.00% | — | 11198.00% | -38.40% | -2.91 | 2356.59% | 0.00% | 0.00% | 3.72% | -0.08 | -0.10 | — | 1.56 |
| MREO | Mereo BioPharma Group plc | $0.37 | 59.17M | +8,875% | — | — | — | -8.52 | 6.04 | — | -7.48 | — | 6.11 | 0.00% | — | — | -77.58% | 2839.57% | -60.54% | 0.11 | -34.56 | 5.40 | 5.28 | 1.55 | -9997.00% | -10000.00% | 5560.00% | -9.10% | -2.37 | 2010.37% | 0.00% | 0.00% | 3.23% | -6.44 | -9.09 | — | 4.76 |
| SLN | Silence Therapeutics plc | $5.44 | 256.95M | +597% | -16% | — | — | -2.07 | 0.56 | 1.73 | 1.48 | — | 0.60 | 72.70% | -146.38% | -104.74% | -46.39% | 212.32% | -22.47% | 0.00 | — | 11.14 | 10.36 | 2.47 | -3190.00% | 7047.00% | 7223.00% | -90.74% | -4.02 | 227.52% | 0.00% | 0.00% | 70.57% | 1.14 | 1.07 | -1.67 | -2.43 |
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
- CEO
- Andre Choulika
- Employees
- 216
- Beta
- 2.85
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($27.34 ÷ $3.95) − 1 = +592.15% (DCF, example).